De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
TransMedics Group Toekomstige groei
Future criteriumcontroles 5/6
TransMedics Group zal naar verwachting groeien in winst en omzet met respectievelijk 38.6% en 20.5% per jaar. De winst per aandeel zal naar verwachting groeien met 36.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 19.8% zijn.
Belangrijke informatie
38.6%
Groei van de winst
36.5%
Groei van de winst per aandeel
Medical Equipment winstgroei | 17.5% |
Inkomstengroei | 20.4% |
Toekomstig rendement op eigen vermogen | 19.8% |
Dekking van analisten | Good |
Laatst bijgewerkt | 07 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
Returns Are Gaining Momentum At TransMedics Group (NASDAQ:TMDX)
Sep 18TransMedics: Take Profits While The Valuation Is Sky High
Sep 18TransMedics: Wide Moat Player At A Lower Valuation Than Peers
Sep 10TransMedics Group, Inc.'s (NASDAQ:TMDX) P/S Is Still On The Mark Following 25% Share Price Bounce
Aug 28TransMedics: Heart And Lungs Will Drive The Next Leg Higher
Aug 19Analysts Just Made A Meaningful Upgrade To Their TransMedics Group, Inc. (NASDAQ:TMDX) Forecasts
Aug 06TransMedics Group: Providing Long-Term Detailed Forecast And Upgrading To Buy
Aug 04TransMedics Group, Inc. Just Recorded A 66% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 02TransMedics Group Stock: Too Far, Too Fast
Jul 08TransMedics: NOP, Logistics And Transport Are Key Growth Drivers But Stock Is Pricey
Jun 17TransMedics Group (NASDAQ:TMDX) Might Have The Makings Of A Multi-Bagger
Jun 10TransMedics: Transportation Supporting Growth
May 21TransMedics Group: Looking At The Road Ahead After An Exceptional Q1 (Rating Downgrade)
May 06TransMedics Group, Inc. (NASDAQ:TMDX) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Apr 24TransMedics Group: Founder Led Company With Solid Potential
Apr 19Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?
Apr 11TransMedics Group: Emerging Medical Device Market Leader With A Long Growth Runway
Mar 19TransMedics Group: Huge Opportunity In Organ Transplants
Mar 12TransMedics: A Very Expensive Growth Stock
Feb 07With TransMedics Group, Inc. (NASDAQ:TMDX) It Looks Like You'll Get What You Pay For
Jan 23Calculating The Fair Value Of TransMedics Group, Inc. (NASDAQ:TMDX)
Jan 02Does TransMedics Group (NASDAQ:TMDX) Have A Healthy Balance Sheet?
Nov 05This Just In: Analysts Are Boosting Their TransMedics Group, Inc. (NASDAQ:TMDX) Outlook for This Year
Aug 06TransMedics Group (NASDAQ:TMDX) Has Debt But No Earnings; Should You Worry?
Aug 02TransMedics Group, Inc. (NASDAQ:TMDX) Not Lagging Industry On Growth Or Pricing
Jun 29Brokers Are Upgrading Their Views On TransMedics Group, Inc. (NASDAQ:TMDX) With These New Forecasts
May 06Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?
Apr 27Estimating The Intrinsic Value Of TransMedics Group, Inc. (NASDAQ:TMDX)
Apr 09Is TransMedics Group (NASDAQ:TMDX) A Risky Investment?
Jan 16Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 694 | 101 | 128 | 150 | 7 |
12/31/2025 | 583 | 65 | 56 | 87 | 10 |
12/31/2024 | 445 | 48 | -56 | 73 | 9 |
6/30/2024 | 359 | 3 | -221 | 24 | N/A |
3/31/2024 | 297 | -10 | -230 | -8 | N/A |
12/31/2023 | 242 | -25 | -192 | -13 | N/A |
9/30/2023 | 192 | -36 | -165 | -25 | N/A |
6/30/2023 | 151 | -18 | -41 | -33 | N/A |
3/31/2023 | 119 | -28 | -47 | -36 | N/A |
12/31/2022 | 93 | -36 | -58 | -46 | N/A |
9/30/2022 | 72 | -42 | -61 | -48 | N/A |
6/30/2022 | 51 | -48 | -53 | -43 | N/A |
3/31/2022 | 39 | -47 | -45 | -40 | N/A |
12/31/2021 | 30 | -44 | -32 | -29 | N/A |
9/30/2021 | 28 | -38 | -30 | -29 | N/A |
6/30/2021 | 30 | -30 | -27 | -26 | N/A |
3/31/2021 | 25 | -28 | -30 | -29 | N/A |
12/31/2020 | 26 | -29 | -31 | -30 | N/A |
9/30/2020 | 24 | -32 | -31 | -30 | N/A |
6/30/2020 | 24 | -35 | -30 | -30 | N/A |
3/31/2020 | 26 | -36 | -34 | -33 | N/A |
12/28/2019 | 24 | -34 | -32 | -32 | N/A |
9/28/2019 | 21 | -32 | -31 | -31 | N/A |
6/29/2019 | 18 | -29 | -32 | -32 | N/A |
3/30/2019 | 15 | -26 | -27 | -27 | N/A |
12/29/2018 | 13 | -24 | -26 | -26 | N/A |
9/29/2018 | 12 | -21 | -26 | -25 | N/A |
6/30/2018 | 9 | -20 | -24 | -24 | N/A |
3/31/2018 | 8 | -20 | N/A | -23 | N/A |
12/30/2017 | 8 | -21 | N/A | -23 | N/A |
12/31/2016 | 6 | -24 | N/A | -24 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei TMDX ( 38.6% per jaar) ligt boven de spaarquote ( 2.5% ).
Winst versus markt: De winst van TMDX ( 38.6% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.2% per jaar).
Hoge groeiwinsten: De winst van TMDX zal naar verwachting de komende 3 jaar aanzienlijk groeien.
Omzet versus markt: De omzet van TMDX ( 20.5% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).
Hoge groei-inkomsten: De omzet van TMDX ( 20.5% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen TMDX zal naar verwachting over 3 jaar laag zijn ( 19.8 %).